Technical Analysis for DBVTF - Dbv Techs Boulogne Bill

Grade Last Price % Change Price Change
grade F 9.12 -25.85% -3.1800
DBVTF closed down 25.85 percent on Tuesday, June 30, 2020, on 0 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical DBVTF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Hot IPO Pullback Bullish Swing Setup -25.85%
Narrow Range Bar Range Contraction -25.85%
Stochastic Reached Oversold Weakness -25.85%
Gapped Down Weakness -25.85%
Older signals for DBVTF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Medicine Medical Specialties Biopharmaceutical Immunology Immunotherapy Allergy Vaccine Crohn's Disease Bordatella Pertussis Food Allergies Peanut Allergy

Is DBVTF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 52.5
52 Week Low 9.12
Average Volume 32,015
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 33.8363
10-Day Moving Average 21.1937
Average True Range 4.6397
ADX 0.0
+DI 30.5212
-DI 69.2964
Chandelier Exit (Long, 3 ATRs ) 38.5809
Chandelier Exit (Short, 3 ATRs ) 23.0391
Upper Bollinger Band 64.6730
Lower Bollinger Band 2.9996
Percent B (%b) 0.1
BandWidth 182.2699
MACD Line -10.7284
MACD Signal Line -6.8685
MACD Histogram -3.8599
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.1200
Resistance 3 (R3) 9.1200 9.1200 9.1200
Resistance 2 (R2) 9.1200 9.1200 9.1200 9.1200
Resistance 1 (R1) 9.1200 9.1200 9.1200 9.1200 9.1200
Pivot Point 9.1200 9.1200 9.1200 9.1200 9.1200
Support 1 (S1) 9.1200 9.1200 9.1200 9.1200 9.1200
Support 2 (S2) 9.1200 9.1200 9.1200 9.1200
Support 3 (S3) 9.1200 9.1200 9.1200
Support 4 (S4) 9.1200